ESR1 and breast carcinoma: Taken together, our data suggest that HR+ breast cancer cell lines with elevated FGFR1 levels (either because of amplification or increased mRNA levels) require the combination of ER, CDK4/6 and FGFR1 blockade for maximum cell cycle arrest.